Abstract:Erythropoietin (EPO), clinically used as a hematopoietic drug, has received much attention due to its nonhematopoietic effects. EPO reportedly has beneficial effects on obesity and diabetes mellitus. We investigated whether interscapular brown adipose tissue (iBAT: main part of classical BAT) could play a role in EPO's anti-obesity and anti-diabetic effects in diet-induced obese mice. Four-week-old male C57BL/6J mice were fed a high-fat diet (HFD-Con), and half were additionally given an intraperitoneal injection of recombinant human EPO (200 IU/kg) (HFD-EPO) thrice a week for four weeks. At 8 weeks, EPO-injected mice showed significantly reduced body weight with reduced epididymal and subcutaneous white fat mass and unchanged caloric intake and locomotor activity. HOMA-IR (insulin resistance index) and glucose levels during intraperitoneal glucose tolerance test (IPGTT) were significantly lower in HFD-EPO mice than in HFD-Con mice. EPO-injected mice also showed increased oxygen consumption, indicative of metabolic rate, and skin temperature around iBAT tissue masses. EPO significantly upregulated the PRD1-BF1-RIZ1 homologous domain containing 16 (PRDM16), a transcriptional factor with a crucial role in brown adipocyte differentiation. EPO significantly increased phosphorylated signal transducer and activator of transcription 3 (STAT3), which is downstream of erythropoietin receptor (EpoR) and known to stabilize PRDM16. EPO's suppression of myocyte enhancer factor 2c (Mef2c) and microRNA-133a (miR-133a) via β3-adrenergic receptor caused PRDM16 upregulation. EPO-mediated enhancement of EpoR/STAT3 and β-adrenergic receptor/Mef2c/miR-133 pathways dramatically increases total uncoupling protein 1 (UCP1), an essential enzyme for BAT thermogenesis. Furthermore, EPO activated BAT's endocrine functions. EPO facilitated fibroblast growth factor 21 (FGF21) production and excretion in iBAT, associated with reduction of liver gluconeogenesis-related genes. Thus, EPO's improvement of obesity and glucose homeostasis can be attributed to increased iBAT thermogenic capacity and activation of BAT's endocrine functions.

Erythropoietin Ameliorates PA-induced Insulin Resistance Through the IRS/AKT/FOXO1 and GSK-3β Signaling Pathway, and Inhibits the Inflammatory Response in HepG2 Cells.

Erythropoietin Alleviates Hepatic Insulin Resistance Via PPARγ-dependent AKT Activation

Erythropoietin Inhibits Gluconeogenesis And Inflammation In The Liver And Improves Glucose Intolerance In High-Fat Diet-Fed Mice

Glucose Metabolism Was Improved by Erythropoietin Treatment Through Forkhead Box O1-glycogen Synthase Kinase 3β Signaling in Palmitic Acid-Induced HepG2 Cells

Role for Erythropoietin on Insulin Signaling of Palmitate Treated HepG2 Cells

Erythropoietin Alleviates Hepatic Steatosis by Activating SIRT1-mediated Autophagy.

Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes.

Erythropoietin suppresses hepatic steatosis and obesity by inhibiting endoplasmic reticulum stress and upregulating fibroblast growth factor 21.

Protective effects of erythropoietin on lipid metabolism in the liver of ob/ob mice

Erythropoietin Improves Glucose Metabolism And Pancreatic Beta-Cell Damage In Experimental Diabetic Rats

Erythropoietin (EPO) ameliorates obesity and glucose homeostasis by promoting thermogenesis and endocrine function of classical brown adipose tissue (BAT) in diet-induced obese mice

Effect of EPO on PRDM16, FGF21 Expression and STAT Phosphorylation of Brown Adipose Tissue in HFD Mice

Erythropoietin protects pancreatic β-cell line NIT-1 cells against cytokine-induced apoptosis via phosphatidylinositol 3-kinase/Akt signaling.

Erythropoietin Signaling: A Novel Regulator of White Adipose Tissue Inflammation During Diet-Induced Obesity

Erythropoietin ameliorates diabetes-associated cognitive dysfunction in vitro and in vivo

Erythropoietin Improves Hepatic Fibrosis Via Suppression Of Hepatic Stellate Cells And Macrophage Activation

Erythropoietin enhances iron bioavailability in HepG2 cells by downregulating hepcidin through mTOR, C/EBPα and HIF-1α

Hepatoprotective effects of erythropoietin on D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in mice.

Erythropoietin Attenuates 6-Hydroxydopamine-induced Apoptosis Via Glycogen Synthase Kinase 3Β-Mediated Mitochondrial Translocation of Bax in PC12 Cells

Erythropoietin Suppresses D-galactose-induced Aging of Rats Via the PI3K/Akt/Nrf2-ARE Pathway

Erythropoietin Ameliorates Renal Interstitial Fibrosis Via the Inhibition of Fibrocyte Accumulation.